|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0013089,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0031082,
umls-concept:C0031928,
umls-concept:C0034656,
umls-concept:C0144576,
umls-concept:C0205171,
umls-concept:C0205179,
umls-concept:C0220825,
umls-concept:C0450442,
umls-concept:C0600558,
umls-concept:C0871261,
umls-concept:C1318309,
umls-concept:C1517927,
umls-concept:C1704632,
umls-concept:C1706817,
umls-concept:C2698872,
umls-concept:C2911692
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-1-22
|
|
pubmed:abstractText |
Response to neoadjuvant chemotherapy for locally advanced breast cancer can be correlated with long-term outcomes. Surrogate end-point biomarkers may be used to assess response to the treatment. Most reported studies assessed the effects of combination chemotherapy. We assessed the feasibility of obtaining serial core breast biopsies, and correlated rates of apoptosis, proliferation, and expression of related proteins at baseline, during, and after neoadjuvant single agent chemotherapy for locally advanced breast cancer with response.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1078-0432
|
|
pubmed:author |
pubmed-author:CrawfordJeanette GJG,
pubmed-author:EllisMathew JMJ,
pubmed-author:FarhadAhmadA,
pubmed-author:HayesDaniel FDF,
pubmed-author:IsaacsClaudineC,
pubmed-author:NovielliAntonellaA,
pubmed-author:PennanenMarieM,
pubmed-author:SinghBaljitB,
pubmed-author:SlackRebeccaR,
pubmed-author:StearnsVeredV,
pubmed-author:TiberyCeciliaC,
pubmed-author:TsangarisTheodoreT
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
9
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
124-33
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:12538460-Adjuvants, Immunologic,
pubmed-meshheading:12538460-Adult,
pubmed-meshheading:12538460-Aged,
pubmed-meshheading:12538460-Apoptosis,
pubmed-meshheading:12538460-Biopsy,
pubmed-meshheading:12538460-Breast Neoplasms,
pubmed-meshheading:12538460-Cell Division,
pubmed-meshheading:12538460-Clinical Trials as Topic,
pubmed-meshheading:12538460-Doxorubicin,
pubmed-meshheading:12538460-Female,
pubmed-meshheading:12538460-Humans,
pubmed-meshheading:12538460-Immunohistochemistry,
pubmed-meshheading:12538460-In Situ Nick-End Labeling,
pubmed-meshheading:12538460-Middle Aged,
pubmed-meshheading:12538460-Neoplasm Metastasis,
pubmed-meshheading:12538460-Paclitaxel,
pubmed-meshheading:12538460-Pilot Projects,
pubmed-meshheading:12538460-Random Allocation,
pubmed-meshheading:12538460-Time Factors,
pubmed-meshheading:12538460-Treatment Outcome,
pubmed-meshheading:12538460-Tumor Markers, Biological
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer.
|
|
pubmed:affiliation |
Department of Medicine, Lombardi Cancer Center, Georgetown University School of Medicine, Washington, DC 20007, USA. vstearn1@jhmi.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
